Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences

2 years ago

– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY…

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

2 years ago

LG Chem to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its T-cell therapy candidates…

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

2 years ago

ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022ProKidney receives…

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

2 years ago

Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc.,…

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

2 years ago

PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that…

Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

2 years ago

WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of…

Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu

2 years ago

Partnership aims to expand the Transfusion Transmissible Infections, other Infectious Diseases, and clinical diagnostics assay menu on Quotient’s multimodality, multiplexed…

CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal

2 years ago

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN…

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

2 years ago

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022…

Aurora Spine Announces New FDA indication clearance of Lumbar Spinal Stenosis for its ZIP™ series of MIS implants

2 years ago

CARLSBAD, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),…